Coherus Biosciences | CHRS - Cost Of Sales

Stock Price
1.61
Daily Change
-0.40 -19.90%
Monthly
0.63%
Yearly
36.44%
Q1 Forecast
2.39

Coherus Biosciences reported $2.65M in Cost of Sales for its fiscal quarter ending in March of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Akebia Therapeutics USD 8.13M 2.41M Mar/2025
ALKERMES USD 51.59M 2.13M Sep/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 16.89M 18.51M Mar/2025
Amgen USD 1.79B 128M Dec/2025
Baxter International USD 2.4B 512M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Coherus Biosciences USD 2.65M 31.2M Mar/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Fujifilm JPY 509.85B 19.73B Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Merck USD 3.32B 531M Dec/2025
Myriad Genetics USD 61.9M 600K Sep/2025
Pacira USD 48.6M 6.59M Sep/2025
Perrigo USD 666.2M 27.2M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 23.32M 7.83M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Teva Pharmaceutical Industries USD 2.06B 120M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025
Zoetis USD 743M 60M Dec/2025